IGC Pharma, Inc. (IGC)
NYSEAMERICAN: IGC · Real-Time Price · USD
0.2829
-0.0078 (-2.67%)
Mar 12, 2026, 12:18 PM EDT - Market open
IGC Pharma Employees
IGC Pharma had 70 employees as of March 31, 2025. The number of employees increased by 3 or 4.48% compared to the previous year.
Employees
70
Change (1Y)
3
Growth (1Y)
4.48%
Revenue / Employee
$15,800
Profits / Employee
-$92,086
Market Cap
27.10M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Mar 31, 2025 | 70 | 3 | 4.48% | 70 | 0 |
| Mar 31, 2024 | 67 | 6 | 9.84% | 67 | 0 |
| Mar 31, 2023 | 61 | 9 | 17.31% | 61 | 0 |
| Mar 31, 2022 | 52 | 2 | 4.00% | 52 | 0 |
| Mar 31, 2021 | 50 | 0 | - | 50 | 0 |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Boundless Bio | 64 |
| Passage Bio | 60 |
| Evaxion | 46 |
| Senti Biosciences | 34 |
| NeuroSense Therapeutics | 17 |
| BriaCell Therapeutics | 16 |
| FibroBiologics | 15 |
| Hyperion DeFi | 14 |
IGC News
- 14 days ago - IGC Pharma Files Utility Patent Applications Covering AI-Based Data Harmonization Architecture Supporting Alzheimer's Research - Accesswire
- 16 days ago - IGC Pharma Notes Updated Research Coverage from Ascendiant Capital Markets - Accesswire
- 17 days ago - IGC Pharma Adds Visionary Investigators Network as Clinical Site to Phase 2 CALMA Trial - Accesswire
- 23 days ago - IGC Pharma Secures North American Composition Protection for IGC-AD1 as Phase 2 CALMA Enrollment Advances - Accesswire
- 4 weeks ago - IGC Pharma to Participate in Fireside Chat With Ascendiant Capital Markets - Accesswire
- 4 weeks ago - IGC Pharma Announces Equity Research Update by Alliance Global Partners - Accesswire
- 4 weeks ago - IGC Pharma Expands Phase 2 CALMA Trial into Colombia's Premier Alzheimer's Research Center - Accesswire
- 5 weeks ago - IGC Pharma Reaches 70% Enrollment in Phase 2 CALMA Trial Evaluating IGC-AD1 for Alzheimer's Agitation - Accesswire